Conv. Plasma
Nigella Sativa
Nitric Oxide
Peg.. Lambda

Home   COVID-19 treatment studies for Proxalutamide  COVID-19 treatment studies for Proxalutamide  C19 studies: Proxalutamide  Proxalutamide   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19 Patients -an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial
Medeiros et al., ResearchGate (Preprint), NCT04728802 (history)
Medeiros et al., Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19 Patients -an Analysis of the Radiological.., ResearchGate (Preprint), NCT04728802
Jul 2021   Source   PDF  
  All Studies   Meta
Analysis of radiological findings from the Proxa-Rescue AndroCoV trial showing that proxalutamide significantly improves lung opacities compared to placebo. NCT04728802 (history).
Medeiros et al., 1 Jul 2021, preprint, 23 authors, trial NCT04728802 (history).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperProxalutamideAll
Abstract: See discussions, stats, and author profiles for this publication at: Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19 Patients -an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial Preprint · July 2021 DOI: 10.1101/2021.07.01.21259656 CITATIONS READS 2 654 23 authors, including: Claudia Elizabeth Thompson Ricardo Ariel Zimerman Universidade Federal de Ciências da Saúde de Porto Alegre Hospital da Brigada Militar de Porto Alegre 171 PUBLICATIONS 677 CITATIONS 31 PUBLICATIONS 173 CITATIONS SEE PROFILE SEE PROFILE Carlos Gustavo Wambier Cadegiani Flávio Alpert Medical School - Brown University Applied Biology 152 PUBLICATIONS 1,268 CITATIONS 119 PUBLICATIONS 749 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Adrenal Fatigue as a myth View project The Sion Publishing House View project All content following this page was uploaded by Cadegiani Flávio on 01 July 2021. The user has requested enhancement of the SEE PROFILE Proxalutamide (GT0918) Improves Lung Injury in Hospitalized COVID-19 Patients – an Analysis of the Radiological Findings of the Proxa-Rescue AndroCoV Trial Flávio Adsuara Cadegiani, MD, PhD1,2*, Daniel do Nascimento Fonseca, MD3, Michael do Nascimento Correia, MD4, Renan Nascimento Barros, MD5, Dirce Costa Onety, MD3, Karla Cristina Petruccelli Israel, MD6,7, Emilyn Oliveira Guerreiro3, José Erique Miranda Medeiros3, Raquel Neves Nicolau3, Luiza Fernanda Mendonça Nicolau3, Rafael Xavier Cunha3, Maria Fernanda Rodrigues Barroco3, Patrícia Souza da Silva3, Raysa Wanzeller de Souza Paulain, MD5, Claudia Elizabeth Thompson, PhD8, Ricardo Ariel Zimerman, MD9, Carlos Gustavo Wambier, MD, PhD10, Andy Goren, MD2 1Corpometria Institute, Brasilia, Brazil. Applied Biology, Inc. Irvine, CA, USA. 2 3Samel & Oscar Nicolau Hospitals, Manaus, Brazil 4Hospital Regional José Mendes, Itacoatiara, Amazonas, Brazil 5Hospital Municipal Jofre Cohen, Parintins, Amazonas, Brazil 6Centro de Doenças Renais do Amazonas, Manaus, Brazil 7Programa de Pós-Graduação em Medicina Tropical – FMT/UEA, Manaus, Brazil 8Department of Pharmacosciences, Universidade Federal de Ciências da Saúde de Porto Alegre 9Hospital da Brigada Militar, Porto Alegre, Brazil 10Department of Dermatology, Alpert Medical School of Brown University, Providence, RI, USA. *Corresponding author: Flavio Adsuara Cadegiani, MD, PhD Applied Biology, Inc. 17780 Fitch Irvine, CA 92614 Abstract Word Count: 407 Text-Only Word Count: 2914 Total Number of References: 26 Tables (#): 2 Figures (#): 2 Abstract Introduction: Antiandrogen are good candidates against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) disease (COVID-19) due to the inhibition of its entry into host cells by the suppression of TMPRSS2, an enzyme that primes the SARSCoV-2 spike (S) protein and is key for its cell entry. Proxalutamide is a secondgeneration nonsteroidal anti-androgen (NSAA) with strong activities on androgen receptor (AR) antagonism, suppression of AR nuclear expression, and downregulation of the membrane-attached angiotensin converting enzyme-2 (ACE2). The efficacy of proxalutamide was previously demonstrated for early COVID-19 patients, and has now demonstrated efficacy to reduce deaths in hospitalized COVID-19 patient in a doubleblind, placebo-controlled randomized clinical..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop